Skip to main content
. 2021 Nov 22;19:473. doi: 10.1186/s12967-021-03136-2

Fig. 5.

Fig. 5

Ibrutinib decreases CD8 T cell proliferation and exhaustion marker expression on CLL patient T cells in vitro. PBMC from Healthy Donor (HD, n = 4) or treatment naive CLL patients (n = 4) were stained with CTV, treated with ibrutinib, zanubrutinib, or acalabrutinib or vehicle control, and stimulated with T cell activation beads. PD-1, TIM3 and LAG3 cell surface expression (MFI) was measured on individual generations of dividing CD8 + and CD4 + T cells from CLL patients (CD8 + (A), CD4 + (B)) and healthy donors (CD8 + (C), CD4 + (D))